Home > Insider Trading > Filing (0001104659-23-126431)

Filing Details

Accession Number:: 0001104659-23-126431
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2023-12-15 16:34:16
Reporting Period:: 2023-12-13

Accepted Time:: 2023-12-15 16:34:16
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1175151	Cytosorbents Corp	CTSO	Surgical & Medical Instruments & Apparatus (3841)	980373793

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1751617	Efthymios Deliargyris	C/O Cytosorbents Corporation 305 College Road East Princeton NJ 08540	Chief Medical Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2023-12-13	22,557	$1.33	348,433	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Common Stock Warrant (Right to Buy)	Acquisiton	2023-12-13	7,894	$0.00	7,894	$2.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
7,894	2023-12-13	2028-12-13	No	4	P	Direct

Footnotes

These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the "Company"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the "Common Stock") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant.
Includes: (i) the following restricted stock units ("RSUs") (which vest as to two-thirds of the award on the first anniversary of the date of grant and one-third of the award on the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date) that will settle into shares of Common Stock upon vesting: 55,000 RSUs granted on July 7, 2023 and unvested as of the date hereof;
(continued from footnote 2) (ii) the following RSUs that will be settled into Common Stock upon vesting upon a "Change In Control" of the Company as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 120,000 RSUs granted on April 9, 2020 and (b) 55,000 RSUs granted on August 10, 2022;
(continued from footnote 3) (iii) the following RSUs that will settle into Common Stock upon vesting: (a) 20,000 RSUs granted on April 9, 2020 and unvested on the date hereof (which cliff vest on the fourth anniversary of the grant date, subject to the reporting person's continued service as of the applicable vesting date) and (b) 17,334 RSUs granted on August 10, 2022 and unvested on the date hereof (which vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date); and
(continued from footnote 4) (iv) 81,099 shares of Common Stock owned by the reporting person.